top of page
  • Writer's picturePam King Sams

Penn Medicine and Children’s Hospital of Philadelphia to Host Symposium Cell and Gene Therapies

“Cellicon Valley ’21” to Be Held Virtually with Experts from Around the World.

PHILADELPHIA— Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor (CAR) T cell therapy and more.

As home to the first U.S Food and Drug Administration-approved cell and gene therapies, Penn Medicine and CHOP are international leaders who have helped propel Philadelphia into “Cellicon Valley”— the name coined by Penn researchers to describe the region’s emergence as a hub for cell and gene therapy.

The first day of the “Cellicon Valley ’21” symposium will be comprised of eight concurrent sessions in the morning, with talks from experts in academia and industry covering CRISPR, the future of cellular therapies for pediatric patients, vaccines to boost CAR T cells, and costs of care, among other topics. Live, virtual Q&As will be held in the afternoon for each of the sessions. The second day will feature plenary talks on “tomorrow’s CARs,” treating patients with cellular therapies during the pandemic, and the expansion of CARs around the world, including Brazil, Costa Rica, and India.

The symposium open to all nurses, healthcare professionals at no cost.

The symposium will close with a talk on the future of cell and gene therapy by symposium co-chair Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in Penn’s Perelman School of Medicine and director of the Center for Cellular Immunotherapies.

Other co-chairs and speakers include Stephan Grupp, MD, PhD, chief of the Cell Therapy and Transplant Section in the division of Oncology and director of the Cancer Immunotherapy Program at CHOP, David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Cell Therapy and Transplantation in Penn's Abramson Cancer Center, and Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy in Penn’s Perelman School of Medicine.

University of Pennsylvania President Amy Gutmann, J. Larry Jameson, MD, PhD, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the Perelman School of Medicine, and Kevin B Mahoney, CEO of the University of Pennsylvania Health System, will also give remarks.

13 views0 comments


bottom of page